Conor E. Steuer, MD
The treatment of patients with non–small cell lung cancer (NSCLC) who have oncogenic rearrangements, such as ALK
, has rapidly advanced in recent years with the rise of second- and third-generation inhibitors, said Conor E. Steuer, MD. However, with that progress, sequencing questions have emerged as well as the challenge of acquired resistance.
... to read the full story